Evidence map›Paper›PMID 39928089›Full record

ReviewDie Ophthalmologie2025

[Secondary choroidal neovascularization-Really so common?]

Ulrike Brocks, Martin Ziegler, Clemens Lange, Lebriz Altay, Laurenz Pauleikhoff

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ulrike BrocksKlinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. u.brocks@uke.de.
Martin ZieglerAugenzentrum am St. Franziskus Hospital, Münster, Deutschland.
Clemens LangeAugenzentrum am St. Franziskus Hospital, Münster, Deutschland.
Lebriz AltayKlinik für Augenheilkunde, Universitätsklinikum Köln, Köln, Deutschland.
Laurenz PauleikhoffKlinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The occurrence of secondary choroidal neovascularization (CNV) is a complication in patients with chronic central serous chorioretinopathy. The diagnosis is made using multimodal imaging. The treatment usually includes intravitreal anti-vascular endothelial growth factor (VEGF) injections. A combination with photodynamic therapy can be useful; however, the response to anti-VEGF treatment is significantly reduced compared to other indications for CNV, so that an irreversible decrease of visual acuity often remains.

Indexed as

Central Serous ChorioretinopathyChoroidal NeovascularizationAngiogenesis InhibitorsHumansIntravitreal InjectionsPhotochemotherapyVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorCentral serous chorioretinopathyMultimodal imagingPhotodynamic therapyTherapy

Identifiers

PMID39928089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.